|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
03692 HANSOH PHARMA
Nominal 
18.520 +0.260 (+1.424%) | 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 6,505,501 | 44.207% | 10,103,806 | 9,382,410 | 9,935,141 | 8,690,234 |
| Cost of Sales | (579,218) | 8.173% | (1,030,863) | (867,010) | (870,042) | (801,561) |
| Gross Profit | 5,926,283 | 49.060% | 9,072,943 | 8,515,400 | 9,065,099 | 7,888,673 |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 3,118,186 | 107.895% | 3,766,155 | 2,948,428 | 3,300,082 | 3,098,299 | |
| Taxation | (392,661) | 86.064% | (488,652) | (364,681) | (587,180) | (529,392) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 2,725,525 | 111.470% | 3,277,503 | 2,583,747 | 2,712,902 | 2,568,907 | |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (369,068) | 8.079% | (838,326) | (250,943) | (111,275) | (90,392) |
| Depreciation & Amortisation | 216,767 | 17.249% | 366,381 | 344,602 | 278,467 | 233,274 |
| Directors' Emoluments | -- | -- | 41,912 | 33,123 | 39,608 | 38,207 |
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | 46.000 | 109.091% | 55.000 | 44.000 | 46.000 | 44.000 |
| DPS (cts) | 18.347 | -- | 19.311 | 8.711 | 7.320 | 6.510 |
| Dividend Payout Ratio (%) | 39.885% | -- | 35.110% | 19.797% | 15.913% | 14.795% |
| Cash flow per share ($) | -- | -- | 0.526 | 0.463 | 0.435 | 0.407 |
| NBV per share ($) | 4.701 | -- | 4.347 | 3.824 | 3.382 | 3.020 |
| Remarks: | Real time quote last updated: 22/11/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 2,725,525 |
| %Change | 111.470% |
| EPS / (LPS) | RMB 0.460 |
| NBV Per Share (¥) | RMB 4.701 |